Literature DB >> 1035507

Phase I study of oral mitomycin C.

S T Crooke, M Henderson, M Samson, L H Baker.   

Abstract

This study demonstrates that the gastrointestinal absorption of oral mitomycin C is variable and that myelosuppression correlates most closely with the peak serum concentration. The probable maximal-tolerated dose of oral mitomycin C is 45-50 mg/m2.

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 1035507

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


  6 in total

Review 1.  Intravesical drug delivery. Pharmacokinetic and clinical considerations.

Authors:  M S Highley; A T van Oosterom; R A Maes; E A De Bruijn
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

Review 2.  Adjuvant methods to improve results of local bladder irrigations by chemotherapy for NMIBC.

Authors:  Yuval Freifeld; Yoram Dekel; Avi Stein
Journal:  Curr Urol Rep       Date:  2013-04       Impact factor: 3.092

Review 3.  Interactions between antiretrovirals and antineoplastic drug therapy.

Authors:  Tony Antoniou; Alice L Tseng
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma.

Authors:  R Paroni; A Salonia; A Lev; L F Da Pozzo; G Cighetti; F Montorsi; P Rigatti; R Colombo
Journal:  Br J Clin Pharmacol       Date:  2001-09       Impact factor: 4.335

5.  Pharmacokinetics of UGN-101, a mitomycin-containing reverse thermal gel instilled via retrograde catheter for the treatment of low-grade upper tract urothelial carcinoma.

Authors:  Ahmad Shabsigh; Nir Kleinmann; Angela B Smith; Douglas Scherr; Elyse Seltzer; Mark Schoenberg; Seth P Lerner
Journal:  Cancer Chemother Pharmacol       Date:  2021-03-07       Impact factor: 3.333

6.  Assessment of the efficacy of repeated instillations of mitomycin C mixed with a thermosensitive hydrogel in an orthotopic rat bladder cancer model.

Authors:  F Johannes P van Valenberg; Dalit Strauss-Ayali; Yael Agmon-Gerstein; Astar Friedman; Harm C Arentsen; H Ewout Schaafsma; J Alfred Witjes; Egbert Oosterwijk
Journal:  Ther Adv Urol       Date:  2018-03-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.